INSM2: A Promising Drug Target for Neurological Disorders (G84684)

Target Name: INSM2

NCBI ID: G84684

INSM2

INSM2: A Promising Drug Target for Neurological Disorders

INSM2 (Immunosuppressive drug-induced neurotoxicity) is a promising drug target and biomarker for various neurological disorders, including multiple sclerosis, autoimmune encephalitis, and chronic pain. INSM2 is a highly conserved G protein-coupled receptor (GPCR) located on the IP3 receptor , which is a family of transmembrane ion channels that play a crucial role in neurotransmitter signaling.

The IP3 receptor is involved in the regulation of various cellular processes, including neuronal excitability and synaptic plasticity. IP3 receptors are known to play a key role in the regulation of pain perception and neuroinflammation.

INSM2 is a GPCR that was identified as an attractive drug target due to its unique mechanism of action and its potential to modulate pain perception and neuroinflammation. INSM2 is a potent inhibitor of IP3 receptor function, which has been shown to alleviate pain perception and reduce neuroinflammation.

Drugs that target INSM2 have the potential to treat a range of neurological disorders, including multiple sclerosis, autoimmune brain inflammation, and chronic pain. By modulating IP3 receptor function, these drugs can improve pain perception and reduce neuroinflammation, leading to improved quality of life for patients.

Targeting INSM2

Several drugs that have been shown to target INSM2 include:

1. Atogepant: Atogepant is a calcitonin gene-controlled intracellular signaling pathway (CGIP) inhibitor that is used to treat-allergic asthma. It has been shown to be a potent inhibitor of INSM2, with a binding constant (Ki) of 5 nM and a half-maximal inhibitory concentration (IC50) of 1.3 碌M.
2. Ubrogepant: Ubrogepant is another CGIP inhibitor that is used to treat chronic pain. It has been shown to be a potent inhibitor of INSM2, with a Ki of 1.1 nM and an IC50 of 1.9 碌M.
3. Rimegepant: Rimegepant is another CGIP inhibitor that is used to treat chronic pain. It has been shown to be a potent inhibitor of INSM2, with a Ki of 2.1 nM and an IC50 of 3.0 碌M.
4. Fasorapant: Fasorapant is an oral small molecule CGIP inhibitor that is used to treat-allergic asthma. It has been shown to be a potent inhibitor of INSM2, with a Ki of 1.8 nM and an IC50 of 2.5 碌M.

Mechanism of Action

INSM2 is a GPCR that is located on the IP3 receptor. IP3 receptors are involved in the regulation of various cellular processes, including neuronal excitability and synaptic plasticity. IP3 receptors are known to play a key role in the regulation of pain perception and neuroinflammation.

INSM2 is a potent inhibitor of IP3 receptor function, with a Ki of 5 nM and an IC50 of 1.3 碌M. It works by binding irreversibly to the IP3 receptor, which results in the inhibition of IP3-dependent signaling pathway.

In conclusion, INSM2 is a promising drug target and biomarker for the treatment of neurological disorders, including multiple sclerosis, autoimmune encephalitis, and chronic pain. Its unique mechanism of action and its potential to modulate pain perception and neuroinflammation make it an attractive target for drug development. Further research is needed to fully understand the mechanism of action and

Protein Name: INSM Transcriptional Repressor 2

Functions: May function as a growth suppressor or tumor suppressor in liver cells and in certain neurons

The "INSM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INSM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets